CellCentric Archives

News and Trends 12 Jul 2023

Pfizer kicks $25M into CellCentric

U.K.-based biotechnology company CellCentric has received a strategic investment from Pfizer including $25 million to help finance further development of inobrodib, its first-in-class p300/CBP inhibitor to treat specific types of cancer. Pfizer will support CellCentric with its own clinical development program in multiple myeloma (MM) for 2024, alongside ongoing trials in specific hematological malignancies, through […]

July 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 29 Jun 2023

FDA gives Orphan Drug Designation to CellCentric multiple myeloma drug

CellCentric, a UK-based biotechnology company, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for inobrodib in the treatment of multiple myeloma. Delivered as an oral capsule, inobrodib can be used at home without requiring intensive monitoring. It is a first-in-class drug, with a new mechanism of action. It […]

June 29, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 13 Jun 2023

CellCentric receives FDA Fast Track designation for relapsed refractory multiple myeloma drug

CellCentric has announced that the U.S. Food and Drug Administration (FDA) has granted its novel cancer drug, inobrodib, Fast Track designation for the treatment of patients with relapsed or refractory multiple myeloma. The FDA’s Fast Track designation is designed to aid the development of new treatments, expediting the review of drugs to treat serious conditions […]

June 13, 2023 - 3 minutesmins - By Jim Cornall

In Depth 1 Feb 2023

Cancer: what are the barriers to research?

Everyone imagines a world without cancer, but getting there is difficult. With World Cancer Day coming up on February 4, we took the opportunity to ask some life science company CEOs, CMOs, and chief scientific officers the same question about cancer research. We asked CellCentric CEO, Will West; iOnctura CEO, Catherine Pickering; ISA Pharmaceuticals chief […]

February 1, 2023 - 6 minutesmins - By Jim Cornall

In Depth 1 Feb 2023

How can cancer care be improved?

Labiotech recently asked several biotech experts the same question about tackling cancer, for a special newsletter to commemorate World Cancer Day on February 4. The 2023 theme is Close the Care Gap. The question, what are the biggest opportunities to improve cancer care, brought responses from Versameb CEO, Klaas Zuideveld; ImaginAb CEO, Ian Wilson; ISA […]

February 1, 2023 - 7 minutesmins - By Jim Cornall

News and Trends 16 Dec 2022

Beyond Biotech podcast 26: CellCentric, MicrofluidX, Potter Clarkson

This week, we have three guests. We have conversations with Antoine Espinet, CEO of MicrofluidX; Will West, CEO of CellCentric; and Sara Holland, patent attorney at Potter Clarkson. MicrofluidX raises £3.3M to develop advanced therapy manufacturing platform MicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, today announces £3.3 million […]

December 16, 2022 - 5 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us